Fast Five Quiz: Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Management

Jafar Kafaie, MD, PhD

Disclosures

June 24, 2021

Figure 1. Contrast-enhanced, axial, T1-weighted MRI of the lumbar spine showing thickening and enhancement of the nerve roots of the cauda equina. This is a consequence of CIDP, a neurologic disorder characterized by progressive weakness and impaired sensory function in the legs and arms.

In addition to targeting underlying disease processes in CIDP, addressing the functional deficits caused by the disease is central to management. Because this rare disease affects the peripheral nerves, damaging the myelin sheath, patients with CIDP often experience muscle weakness, numbness or tingling, and fatigue. Tricyclic antidepressants are used frequently for the treatment of neuropathic pain. Antiepileptic medications are also effective.

Learn more about the clinical presentation of CIDP.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as:

processing....